Analyst Expectations For Tango Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Tango Therapeutics (NASDAQ:TNGX) has been analyzed by 7 analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target is $13.71, down 10.57% from the previous $15.33. Recent analyst actions include both raises and lowers in price targets, reflecting dynamic market conditions. Tango Therapeutics is a biotechnology company focused on precision oncology therapies.
August 08, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Tango Therapeutics (NASDAQ:TNGX) has received mixed analyst ratings, with a 12-month price target average of $13.71, down 10.57% from the previous $15.33. Recent analyst actions include both raises and lowers in price targets, reflecting dynamic market conditions.
The mixed analyst ratings and the downward revision of the average price target suggest a neutral short-term impact on TNGX's stock price. The dynamic market conditions and recent adjustments in price targets indicate uncertainty among analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100